Warner, Tim

Tim Warner

Professor of Vascular Inflammation

Tim Warner graduated in pharmacology in 1986 from King’s College London. He then moved to the newly established William Harvey Research Institute to pursue his PhD studies under the supervision of Prof. Sir John Vane (Nobel Laureate, 1982) during which time he was awarded the Premier Prix Annuel de Recherche en Phlébologie. In 1989 he completed his PhD and went to pursue his post-doctoral studies with Ferid Murad (Nobel Laureate 1998) at Northwestern University and Abbott Laboratories, Chicago, USA. He returned to the William Harvey Research Institute in 1992, being awarded a British Heart Foundation lectureship in 1995. He was promoted Reader in Pharmacology in 1999 and awarded a personal chair in Vascular Inflammation in 2000, at which time he was the recipient of the British Pharmacology Society’s Novartis Prize.  Prof. Warner has been listed by the Institute for Scientific Information among the top 0.5% of cited pharmacologists.  Currently he is also Deputy Dean for Research in the School of Medicine and Dentistry and Deputy Director (Research & Innovation) of QMUL’s Life Science Initiative.  He is a Fellow of the British Pharmacological Society, the American Heart Association and the Society of Biology, he is also a member of the British Society for Cardiovascular Research, International Society for Hypertension Research and the International Society on Thrombosis and Haemostasis.  Prof. Warner is currently principal editor of the journal ‘Platelets’. 

Summary of Research

Prof. Warner’s main focus of current research is the roles of different enzyme pathways in the formation of vasoactive mediators such as prostaglandin I2, thromboxane A2 and nitric oxide in blood vessels and blood cells, and so to the control of platelet reactivity within the circulation. Research into prostaglandin formation is supported by programme grant funding from the Wellcome Trust to Prof. Warner in collaboration with Prof. Jane Mitchell at Imperial College. Locally, researchers into platelet reactivity are being pursued in collaboration with clinical colleagues in the Trauma Department, the Ernest Cooke Vascular & Microvascular Unit, and the Cardiac Directorate of the Barts & the London NHS Trust. The British Heart Foundation is currently funding research into the effects of platelet-derived eicosanoids and the pharmacology of anti-platelet drugs.  Prof. Warner has also received funding from AstraZeneca and the William Harvey Research Foundation to pursue investigations into interactions between different pathways of platelet activation and their relevance to therapy in particular patient groups.

More information about research group and projects can be found here.

 

Members of the Group

Dr Paul Amstrong; Dr Melissa Chan; Dr Marilena Crescente; Dr Paul Vulliamy; Ms Harriet Allen; Ms Melissa Hayman; Ms Laura Menke; Ms Ivana Vojnovic.

Teaching 

Prof. Warner is co-ordinator of the William Harvey Research Institute 4 year PhD scheme funded by the British Heart Foundation. He also contributes to teaching of MB BS, BSc, MRes and MSc students.

Key Publications

For a full list of publist publications click here

Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1
Rauzi F, Kirkby NS, Edin ML, Whiteford J, Zeldin DC, Mitchell JA, Warner TD.
FASEB J. 2016 Sep 15. pii: fj.201600530R. 

Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy
Hoefer T, Armstrong PC, Finsterbusch M, Chan MV, Kirkby NS, Warner TD.
Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2122-33.  

Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction
Armstrong PC, Kirkby NS, Chan MV, Finsterbusch M, Hogg N, Nourshargh S, Warner TD.
Blood. 2015 Sep 3;126(10):e11-8. 

Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation
Kirkby NS, Reed DM, Edin ML, Rauzi F, Mataragka S, Vojnovic I, Bishop-Bailey D, Milne GL, Longhurst H, Zeldin DC, Mitchell JA, Warner TD.
FASEB J. 2015 Nov;29(11):4568-78. 

Ahmetaj-Shala B, Kirkby NS, Knowles R, Al'Yamani M, Mazi S, Wang Z, Tucker AT, Mackenzie L, Armstrong PC, Nüsing RM, Tomlinson JA, Warner TD, Leiper J, Mitchell JA. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation. 2015 Feb 17;131(7):633-42.

Lordkipanidzé M, Lowe GC, Kirkby NS, Chan MV, Lundberg MH, Morgan NV, Bem D, Nisar SP, Leo VC, Jones ML, Mundell SJ, Daly ME, Mumford AD, Warner TD, Watson SP; UK Genotyping and Phenotyping of Platelets Study Group.Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. Blood. 2014 Feb 20;123(8):e11-22.

Kirkby NS, Lundberg MH, Chan MV, Vojnovic I, Solomon AB, Emerson M, Mitchell JA, Warner TD.  (2013). Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci USA. Sep 24;110(39):15782-7.

Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclo-oxygenase-1 and not cyclo-oxygenase-2 is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA. 2012;109(43):17597-602. 

Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Antiplatelet actions of statins and fibrates are mediated by PPARs. (2009) Arterioscler Thromb Vasc Biol.,  29:706-711

Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD, Bishop-Bailey D. Nongenomic signaling of the retinoid x receptor through binding and inhibiting Gq in human platelets. (2007) Blood.,109:3741-3744

Mitchell, J.A., Lucas, R., Vojnovic, I., Hasan, K., Pepper, J.R. and Warner, TD. (2006). Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J., 20: 2468-2475.

Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid x receptor in the vasculature. (2004) Proc Natl Acad Sci U S A., 101:3668-3673

Bishop-Bailey, D. and Warner, TD. (2003). Rosiglitazone induces vascular smooth muscle cell prostanoid production: indomethacin acts as a PPARg antagonist. FASEBJ, 17, 1925-1927.

Bishop-Bailey D, Hla T, Warner TD. Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. (2002) Circulation research., 91:210-217

Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. (1999) Proc Natl Acad Sci U S A.,  96:7563-7568

 

 

 

^ Back to Top